Background:The incidence of clear cell renal cell carcinoma(ccRCC)is globally high;however,despite the introduction of innovative drug therapies,there remains a lack of effective biomarkers for evaluating treatment re...Background:The incidence of clear cell renal cell carcinoma(ccRCC)is globally high;however,despite the introduction of innovative drug therapies,there remains a lack of effective biomarkers for evaluating treatment response.Recently,Caspase recruiting domain-containing protein 11(CARD11)has garnered attention due to its significant association with tumor development and the immune system.Methods:The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry.The focus of this study is on the epigenomic modifications of CARD11,its expression of ccRCC immunophenotype,and its correlation with response to immunotherapy and targeted therapy.Furthermore,to investigate the mechanism of this molecule’s influence on different biological behaviors of cells,cell tests in vitro have been conducted to observe the impact of its expression level.Results:CARD11 expression was upregulated which may be mainly modified by body methylation and was correlated with poor prognosis in ccRCC.In the tumor microenvironment of ccRCC,CARD11 expression was positively correlated with increased T lymphocyte infiltration and increased expression of inhibitory immune checkpoints.Moreover,ccRCC patients with high CARD11 expression had a better response to immunotherapy and targeted therapy.The knockdown of CARD11 ultimately suppressed the proliferation,migration,and invasion capabilities of ccRCC cells while simultaneously enhancing tumor cell apoptosis.Conclusion:We identified CARD11 as a novel therapeutic biomarker for immunotherapy and targeted therapy in ccRCC.展开更多
目的观察弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma)中CARD11与Bcl-2的表达情况,探讨它们在弥漫性大B细胞淋巴瘤中不同免疫分型中的表达及相互关系。方法选取弥漫性大B细胞淋巴瘤60例和反应性增生的淋巴结20例,采用组织芯片...目的观察弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma)中CARD11与Bcl-2的表达情况,探讨它们在弥漫性大B细胞淋巴瘤中不同免疫分型中的表达及相互关系。方法选取弥漫性大B细胞淋巴瘤60例和反应性增生的淋巴结20例,采用组织芯片技术和免疫组织化学方法对弥漫性大B细胞淋巴瘤进行免疫分型并检测弥漫性大B细胞淋巴瘤免疫学类型GCB和ABC型中CARD11和Bcl-2表达情况。结果 (1)免疫分型60例弥漫性大B细胞淋巴瘤中免疫类型GCB25例,ABC35例。(2)60例弥漫性大B细胞淋巴瘤中免疫类型中CARD11与Bcl-2的表达情况:免疫类型GCB中CARD11的阳性率为24.0%,ABC中CARD11的阳性率为57.4%,两者之间P<0.05;GCB中Bcl-2的阳性率为32.0%,ABC中Bcl-2的阳性率为62.9%,两者之间P<0.05。结论①CARD11、NF-κB高表达与弥漫性大B细胞淋巴瘤的ABC类型相关。展开更多
基金supported by grants from the Guangdong Provincial Department of Finance Project in 2022(KS0120220267,KS0120220268,KS0120220272,KS0120220271)Guangdong Basic and Applied Basic Research Natural Science Funding(2023A1515012485)+1 种基金Science and Technology Projects in Guangzhou(202102020058)Launch funding of the National Natural Science Foundation of China(8210101099).
文摘Background:The incidence of clear cell renal cell carcinoma(ccRCC)is globally high;however,despite the introduction of innovative drug therapies,there remains a lack of effective biomarkers for evaluating treatment response.Recently,Caspase recruiting domain-containing protein 11(CARD11)has garnered attention due to its significant association with tumor development and the immune system.Methods:The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry.The focus of this study is on the epigenomic modifications of CARD11,its expression of ccRCC immunophenotype,and its correlation with response to immunotherapy and targeted therapy.Furthermore,to investigate the mechanism of this molecule’s influence on different biological behaviors of cells,cell tests in vitro have been conducted to observe the impact of its expression level.Results:CARD11 expression was upregulated which may be mainly modified by body methylation and was correlated with poor prognosis in ccRCC.In the tumor microenvironment of ccRCC,CARD11 expression was positively correlated with increased T lymphocyte infiltration and increased expression of inhibitory immune checkpoints.Moreover,ccRCC patients with high CARD11 expression had a better response to immunotherapy and targeted therapy.The knockdown of CARD11 ultimately suppressed the proliferation,migration,and invasion capabilities of ccRCC cells while simultaneously enhancing tumor cell apoptosis.Conclusion:We identified CARD11 as a novel therapeutic biomarker for immunotherapy and targeted therapy in ccRCC.
文摘目的观察弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma)中CARD11与Bcl-2的表达情况,探讨它们在弥漫性大B细胞淋巴瘤中不同免疫分型中的表达及相互关系。方法选取弥漫性大B细胞淋巴瘤60例和反应性增生的淋巴结20例,采用组织芯片技术和免疫组织化学方法对弥漫性大B细胞淋巴瘤进行免疫分型并检测弥漫性大B细胞淋巴瘤免疫学类型GCB和ABC型中CARD11和Bcl-2表达情况。结果 (1)免疫分型60例弥漫性大B细胞淋巴瘤中免疫类型GCB25例,ABC35例。(2)60例弥漫性大B细胞淋巴瘤中免疫类型中CARD11与Bcl-2的表达情况:免疫类型GCB中CARD11的阳性率为24.0%,ABC中CARD11的阳性率为57.4%,两者之间P<0.05;GCB中Bcl-2的阳性率为32.0%,ABC中Bcl-2的阳性率为62.9%,两者之间P<0.05。结论①CARD11、NF-κB高表达与弥漫性大B细胞淋巴瘤的ABC类型相关。
